Table 2

Prevalence of warfarin prescription, stratified by severity of kidney disease

 eGFR group
≥120 (N=278)105–119 (N=2018)90–104 (N=13 257)60–89 (N=62 174)45–59 (N=26 939)30–44 (N=13 411)15–29 (N=3787)<15 (N=679)Dialysis (N=645)Total (N=123 188)
Warfarin receipt at 90 days57.2%60.4%61.6%56.7%55.0%52.5%52.1%46.4%62.3%56.3%
Any warfarin during follow-up61.5%68.4%70.2%64.6%62.6%59.7%58.4%52.9%69.9%64.0%
Unadjusted OR of warfarin receipt at 90 days0.83 (0.65–1.06)0.95 (0.86–1.04)(reference group)0.82 (0.79–0.85)0.76 (0.73–0.80)0.69 (0.66–0.72)0.68 (0.63–0.73)0.54 (0.46–0.63)1.03 (0.88–1.21)
Adjusted OR of warfarin receipt at 90 days
 Full cohort0.53 (0.40–0.71)0.80 (0.71–0.90)(reference group)1.11 (1.06–1.16)1.15 (1.09–1.21)1.06 (1.00–1.12)1.14 (1.04–1.25)0.78 (0.66–0.93)1.08 (0.90–1.29)
 CHADS2≥10.58 (0.41–0.83)0.85 (0.73–0.98)(reference group)1.11 (1.05–1.17)1.15 (1.09–1.23)1.07 (1.00–1.12)1.14 (1.03–1.25)0.79 (0.66–0.95)1.04 (0.87–1.25)
 CHADS2=00.49 (0.30–0.80)0.77 (0.63–0.94)(reference group)1.08 (0.995–1.18)1.07 (0.96–1.21)0.94 (0.78–1.13)1.09 (0.77–1.56)0.58 (0.32–1.06)1.69 (0.49–5.78)
 Age≥750.76 (0.41–1.39)(reference group)1.07 (0.94–1.23)1.07 (0.94–1.23)0.98 (0.86–1.12)1.12 (0.95–1.31)0.82 (0.63–1.06)1.28 (0.92–1.77)
 Age <750.66 (0.50–0.88)0.91 (0.81–1.02)(reference group)1.01 (0.96–1.06)1.02 (0.96–1.08)0.95 (0.87–1.04)1.02 (0.88–1.19)0.70 (0.55–0.90)0.96 (0.77–1.20)
 Heart failure0.97 (0.43–2.19)0.83 (0.59–1.15)(reference group)1.14 (0.995–1.31)1.16 (1.01–1.34)1.11 (0.96–1.29)1.24 (1.02–1.51)0.79 (0.57–1.10)1.03 (0.77–1.38)
 No heart failure0.48 (0.35–0.66)0.80 (0.71–0.91)(reference group)1.10 (1.05–1.16)1.14 (1.08–1.21)1.05 (0.99–1.12)1.13 (1.02–1.26)0.79 (0.65–0.97)1.15 (0.91–1.45)
  • The values in the parentheses are 95% confidence intervals.